Scott Serels, MD
Urology · Norwalk, CTNPI 1972695054
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 62.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $13,929 and has fallen 96.5% since, to $493 in 2025. Among urology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $182.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$13K
- Caldera Medical, Inc$4K
- Medtronic$1K
- Boston Scientific$895
- Teleflex LLC$309
- Procept Biorobotics Corporation$300
- plus $1K from 22 others
Across 4 payments — averaging $62,502 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$250K
What the payments were for
- Consulting fees$3,30015%
- Speaking & faculty fees$12,70559%
- Travel & lodging$8824%
- Food & beverage$4,23220%
- Education$3211%
- Gifts$2431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 32 | $13,458 |
| Caldera Medical, Inc | 16 | $4,011 |
| Medtronic | 7 | $1,375 |
| Boston Scientific | 11 | $895 |
| Teleflex LLC | 4 | $309 |
| Procept Biorobotics Corporation | 4 | $300 |
| 180 Medical, Inc. | 6 | $241 |
| Axonics, Inc. | 2 | $221 |
| Pfizer | 6 | $172 |
| Urovant Sciences Inc | 6 | $111 |
| AbbVie(2 entities) | 5 | $103 |
| Laborie Medical Technologies Corp. | 1 | $71 |
| Myovant Sciences Inc. | 3 | $47 |
| Tesaro, Inc. | 1 | $43 |
| Accord Healthcare, Inc. | 2 | $36 |
| Calyxo, Inc. | 1 | $33 |
| Acerus Pharmaceuticals Corporation | 1 | $28 |
| Merck | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Hollister Incorporated | 1 | $23 |
| KARL Storz Endoscopy-america | 1 | $23 |
| Agiliti Surgical, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| Coloplast | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$13,048
- Desara$3,655
- AQUABEAM SYSTEM$253
- Solyx SIS System$247
- ALTAVIVA$227
- Vertessa$177
- Axonics r-SNM System$122
- SOLYX$119
- GENERAL ERECTILE DYSFUNCTION$118
- UroLift$115
How this compares
$21,683 in reported general payments places this provider in the 90th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 444 | $422,903 |
| GemtesaVibegron | 215 | $241,607 |
| Mirabegron ErMirabegron | 31 | $19,203 |
| Solifenacin Succinate | 209 | $16,478 |
| Tamsulosin Hcl | 587 | $10,791 |
| Desmopressin Acetate | 69 | $7,505 |
| Oxybutynin Chloride ErOxybutynin Chloride | 213 | $7,251 |
| ImvexxyEstradiol | 21 | $7,168 |
| Trospium Chloride ErTrospium Chloride | 24 | $7,065 |
| Methenamine Hippurate | 51 | $5,224 |
| Potassium Citrate ErPotassium Citrate | 28 | $4,969 |
| Finasteride | 233 | $3,287 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 17 | $2,795 |
| Estradiol | 33 | $2,148 |
| Trimethoprim | 80 | $1,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $13,458 | $422,903444 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $25 | $241,607215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 156 urology providers in Connecticut.
Other urology in Norwalk
- Stephen BatterNorwalk$6K
- Jonathan BernieNorwalk$4K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.